Ethic Inc. Sells 1,843 Shares of Bio-Rad Laboratories, Inc. $BIO

Ethic Inc. decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 71.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 726 shares of the medical research company’s stock after selling 1,843 shares during the quarter. Ethic Inc.’s holdings in Bio-Rad Laboratories were worth $204,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BIO. Beacon Investment Advisory Services Inc. bought a new position in shares of Bio-Rad Laboratories during the third quarter worth $211,000. Blue Trust Inc. lifted its holdings in Bio-Rad Laboratories by 5.9% during the third quarter. Blue Trust Inc. now owns 1,607 shares of the medical research company’s stock worth $451,000 after acquiring an additional 90 shares in the last quarter. CWM LLC grew its stake in Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 91 shares during the period. Pacer Advisors Inc. increased its holdings in shares of Bio-Rad Laboratories by 159.9% in the third quarter. Pacer Advisors Inc. now owns 3,704 shares of the medical research company’s stock worth $1,039,000 after acquiring an additional 2,279 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of Bio-Rad Laboratories by 52.9% during the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on BIO shares. Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Citigroup increased their price objective on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Finally, Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, November 22nd. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $358.50.

Insider Activity

In related news, EVP James Barry sold 700 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $306.18, for a total transaction of $214,326.00. Following the sale, the executive vice president owned 510 shares in the company, valued at approximately $156,151.80. This represents a 57.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $324.22 on Thursday. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $373.69. The company’s fifty day simple moving average is $311.75 and its 200-day simple moving average is $290.89. The firm has a market cap of $8.75 billion, a PE ratio of -13.34 and a beta of 1.18. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%. The business had revenue of $653.00 million during the quarter, compared to analyst estimates of $651.30 million. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The firm’s quarterly revenue was up .5% on a year-over-year basis. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.